Skip to content

Efficacy and safety of combination therapy of intense pulsed light and topical tranexamic acid in the treatment of melasma

Efficacy and safety of combination therapy of intense pulsed light and topical tranexamic acid in the treatment of melasma

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105598
Enrollment
Unknown
Registered
2025-07-07
Start date
2023-01-06
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Interventions

one:Use Yifeng tranexamic acid plaster
two:Not used Yifeng tranexamic acid plaster

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Ages 18-60, gender not restricted; (2) Meets the diagnosis criteria of melasma, there must be brown to dark brown patches on the face with clear boundaries, without inflammatory manifestations and scales, and other diseases that cause pigmentation are excluded, and other characteristics may be combined;(3) Confirmed as epidermal type, dermal type, or mixed type of melasma by Wood lamp; (4) Fitzpatrick skin typing 3or4; (5) Able to adhere to the treatment and did not use other methods of treatment during the follow-up period; (6) Subjects voluntarily participate need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant and lactating women; (2) Patients with severe heart, liver, or kidney dysfunction; (3) Those have used other skin-lightening products and medications, chemical peeling, laser, and other treatment methods within the past month; (4) Those who have taken isotretoin or oral contraceptives within the past month; (5) Facial edema, ulceration, erosion, or recurrent herpes infection; (6) acne or active facial dermatitis, sensitive skin; (7) History of hypertrophic scarring or keloid scars; (8) Those who cannot adhere to treatment cannot avoid excessive exposure to sunlight; (9) Patients with psychiatric disorders or severe systemic diseases.

Design outcomes

Primary

MeasureTime frame
Melanin;Brown spot;Area of melasma;

Secondary

MeasureTime frame
Moisture content;Oil content;Erythema index;Ultraviolet spots;Texture;Wrinkle;Pore;Porphyrin;Patient satisfaction;

Countries

China

Contacts

Public ContactYan Wu,Yuanyuan Xu

Department of Dermatology, The First Hospital of China Medical University

xyy17101205@163.com+86 138 4016 5696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026